Literature DB >> 15113896

Unspliced Rous sarcoma virus genomic RNAs are translated and subjected to nonsense-mediated mRNA decay before packaging.

Jason J LeBlanc1, Karen L Beemon.   

Abstract

Retroviruses package full-length, unspliced RNAs into progeny virions as dimerized RNA genomes. They also use unspliced RNAs as mRNAs to produce the gag and pol gene products. We asked whether a single Rous sarcoma virus (RSV) RNA can be translated and subsequently packaged or whether genomic packaging requires a nontranslated population of RNAs. We addressed this issue by utilizing the translation-dependent nonsense-mediated mRNA decay (NMD) pathway. NMD is the selective destruction of mRNAs bearing premature termination codons (PTCs). The pathway has been shown to be associated with splicing in higher eukaryotes. Here, we demonstrate that both translation and the cellular factor Upf1 are required for the decay of unspliced, PTC-bearing RSV RNA by the NMD pathway. To address the relationship between RNA translation and packaging, we examined virus produced in cells cotransfected with PTC-bearing retroviral clones and wild-type viral clones. We observed that PTC-bearing transcripts are packaged into viral particles at levels three- to fivefold less than those of control RNAs. Since PTC-mediated degradation requires translation, we conclude that RSV can package progeny virion particles using previously translated RNAs.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15113896      PMCID: PMC400353          DOI: 10.1128/jvi.78.10.5139-5146.2004

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  46 in total

1.  Electron microscope studies of tumor virus RNA.

Authors:  H J Kung; J M Bailey; N Davidson; P K Vogt; M O Nicolson; R M McAllister
Journal:  Cold Spring Harb Symp Quant Biol       Date:  1975

2.  Rous sarcoma virus nucleic acid-binding protein p12 is necessary for viral 70S RNA dimer formation and packaging.

Authors:  C Méric; P F Spahr
Journal:  J Virol       Date:  1986-11       Impact factor: 5.103

3.  The HIV-1 rev trans-activator acts through a structured target sequence to activate nuclear export of unspliced viral mRNA.

Authors:  M H Malim; J Hauber; S Y Le; J V Maizel; B R Cullen
Journal:  Nature       Date:  1989-03-16       Impact factor: 49.962

4.  Deficiency of 60 to 70S RNA in murine leukemia virus particles assembled in cells treated with actinomycin D.

Authors:  J G Levin; P M Grimley; J M Ramseur; I K Berezesky
Journal:  J Virol       Date:  1974-07       Impact factor: 5.103

5.  An avian oncovirus mutant (SE 21Q1b) deficient in genomic RNA: biological and biochemical characterization.

Authors:  M Linial; E Medeiros; W S Hayward
Journal:  Cell       Date:  1978-12       Impact factor: 41.582

6.  Synthesis of murine leukemia virus proteins associated with virions assembled in actinomycin D-treated cells: evidence for persistence of viral messenger RNA.

Authors:  J G Levin; M J Rosenak
Journal:  Proc Natl Acad Sci U S A       Date:  1976-04       Impact factor: 11.205

7.  Nonsense-mediated mRNA decay in Drosophila: at the intersection of the yeast and mammalian pathways.

Authors:  David Gatfield; Leonie Unterholzner; Francesca D Ciccarelli; Peer Bork; Elisa Izaurralde
Journal:  EMBO J       Date:  2003-08-01       Impact factor: 11.598

8.  Evidence for crossing-over between avian tumor viruses based on analysis of viral RNAs.

Authors:  K Beemon; P Duesberg; P Vogt
Journal:  Proc Natl Acad Sci U S A       Date:  1974-10       Impact factor: 11.205

9.  Regulation of Rous sarcoma virus RNA splicing and stability.

Authors:  S Arrigo; K Beemon
Journal:  Mol Cell Biol       Date:  1988-11       Impact factor: 4.272

10.  Stabilities of avian sarcoma virus RNAs: comparison of subgenomic and genomic species with cellular mRNAs.

Authors:  C M Stoltzfus; K Dimock; S Horikami; T A Ficht
Journal:  J Gen Virol       Date:  1983-10       Impact factor: 3.891

View more
  38 in total

1.  A 3' UTR sequence stabilizes termination codons in the unspliced RNA of Rous sarcoma virus.

Authors:  Jason E Weil; Karen L Beemon
Journal:  RNA       Date:  2005-11-21       Impact factor: 4.942

Review 2.  Messenger RNA regulation: to translate or to degrade.

Authors:  Ann-Bin Shyu; Miles F Wilkinson; Ambro van Hoof
Journal:  EMBO J       Date:  2008-02-06       Impact factor: 11.598

Review 3.  Retroviral strategy to stabilize viral RNA.

Authors:  Bao Lin Quek; Karen Beemon
Journal:  Curr Opin Microbiol       Date:  2014-03-13       Impact factor: 7.934

4.  ERV3 and related sequences in humans: structure and RNA expression.

Authors:  Ann-Catrin Andersson; Zhihong Yun; Göran O Sperber; Erik Larsson; Jonas Blomberg
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

5.  Effects of mutations in the human immunodeficiency virus type 1 Gag gene on RNA packaging and recombination.

Authors:  Olga Nikolaitchik; Terence D Rhodes; David Ott; Wei-Shau Hu
Journal:  J Virol       Date:  2006-05       Impact factor: 5.103

Review 6.  Viral Evasion and Manipulation of Host RNA Quality Control Pathways.

Authors:  J Robert Hogg
Journal:  J Virol       Date:  2016-07-27       Impact factor: 5.103

Review 7.  Nonsense-Mediated mRNA Decay: Degradation of Defective Transcripts Is Only Part of the Story.

Authors:  Feng He; Allan Jacobson
Journal:  Annu Rev Genet       Date:  2015-10-02       Impact factor: 16.830

8.  Structural features in the Rous sarcoma virus RNA stability element are necessary for sensing the correct termination codon.

Authors:  Johanna B Withers; Karen L Beemon
Journal:  Retrovirology       Date:  2010-08-05       Impact factor: 4.602

Review 9.  NMD: a multifaceted response to premature translational termination.

Authors:  Stephanie Kervestin; Allan Jacobson
Journal:  Nat Rev Mol Cell Biol       Date:  2012-10-17       Impact factor: 94.444

Review 10.  Mechanisms employed by retroviruses to exploit host factors for translational control of a complicated proteome.

Authors:  Cheryl Bolinger; Kathleen Boris-Lawrie
Journal:  Retrovirology       Date:  2009-01-24       Impact factor: 4.602

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.